The transcription factor CCAAT/enhancer binding protein a (C/EBPa) is important in the regulation of granulopoiesis and is disrupted in human acute myeloid leukemia. In the present study, we sought to identify novel C/EBPa interacting proteins in vivo through immunoprecipitation using mass spectrometrybased proteomic techniques. We identified Max, a heterodimeric partner of Myc, as one of the interacting proteins of C/EBPa in our screen. We confirmed the in vivo interaction of C/EBPa with Max and showed that this interaction involves the basic region of C/EBPa. Endogenous C/EBPa and Max, but not Myc and Max, colocalize in intranuclear structures during granulocytic differentiation of myeloid U937 cells. Max enhanced the transactivation capacity of C/EBPa on a minimal promoter. A chromatin immunoprecipitation assay revealed occupancy of the human C/EBPa promoter in vivo by Max and Myc under cellular settings and by C/EBPa and Max under retinoic acid induced granulocytic differentiation. Interestingly, enforced expression of Max and C/EBPa results in granulocytic differentiation of the human hematopoietic CD34 þ cells, as evidenced by CD11b, CD15 and granulocyte colony-stimulating factor receptor expression. Silencing of Max by short hairpin RNA in CD34 þ and U937 cells strongly reduced the differentiation-inducing potential of C/EBPa, indicating the importance of C/EBPa-Max in myeloid progenitor differentiation. Taken together, our data reveal Max as a novel co-activator of C/EBPa functions, thereby suggesting a possible link between C/EBPa and Myc-Max-Mad network.
Introduction
Hematopoietic differentiation proceeds in a largely irreversible fashion and the role of transcription factors in regulating hematopoiesis has been well documented. This is particularly true for CCAAT/enhancer binding protein a (C/EBPa), one of the lineage-specific transcription factors that is essential for commitment to and development of the granulocytic lineage.
1,2 Recent data have indicated that C/EBPa may also regulate hematopoietic stem cell activity 3 and act as a tumor suppressor gene in acute myeloid leukemias (AMLs), indicating an important role for C/EBPa in the control of cellular proliferation in vivo. 4 Inactivation of C/EBPa is an important event in AML, and ectopic overexpression of C/EBPa leads to differentiation and growth arrest in AML. 5 It is therefore suggested that C/EBPa has a crucial role in regulating the balance between cell proliferation and differentiation, which is crucial for lineage commitment of any cell type. These findings and data from our laboratory indicate that for AML to develop, the activity of C/EBPa must be curbed by either mutations or antagonistic protein-protein interactions.
C/EBPa can form protein-protein interactions with other bZIP and non-bZIP factors. Among them, c-Jun and PU. 1, 6, 7 E2F, p21, and cyclin-dependent kinases CDK2 and CDK4 have been well characterized. [8] [9] [10] Thus, it has become increasingly clear that like most proteins, C/EBPa might not work alone, but in association with other factors regulates gene transcription. However, studies involving protein-protein interactions of C/EBPa at the global proteomic level are lacking. We therefore took advantage of high-throughput proteomics by mass spectrometry (LC-MS/MS) to identify proteins that specifically associate with C/EBPa in vivo. In our screen, Max was identified as a novel interacting partner of C/EBPa in addition to other new and known partners of C/EBPa.
Max is a member of the basic region-helix-loop-helix-leucine zipper protein that belongs to a network of transcription factors, which includes the Myc and Mad families of protein (commonly referred to as a Myc-Max-Mad network). 11 The Myc-Max-Mad proteins can affect different aspects of cell behavior, including cell cycle, proliferation and differentiation, by modulating distinct target genes. [12] [13] [14] [15] Max can form a homo-or a heterodimer and bind specifically to E-box DNA elements in target promoters (consensus CACGTG). 16, 17 To function as transcriptional regulators, the members of the Myc and Mad families must heterodimerize with Max. Whereas Myc-Max activates transcription, Mad-Max and Mnt-Max repress transcription. [18] [19] [20] Indirect evidences to the fact that C/EBPa could be a part of the Myc-Max-Mad network do exist in the literature. 21, 22 However, no direct evidence has been reported so far.
In this study, we have characterized the role of Max as an interacting partner of C/EBPa. We show that Max is an important co-activator of C/EBPa and the stable silencing of Max inhibits the differentiation-inducing potential of C/EBPa. C/EBPa and Max not only colocalize but also the heterocomplex is preferentially formed on the human C/EBPa (hC/EBPa) promoter in vivo during granulocytic differentiation, thereby contributing to increased transactivation and differentiation capacity of C/EBPa.
Materials and methods

Transfection of human hematopoietic CD34 þ progenitors
Human CD34 þ hematopoietic cells were selected, using a magnetic CD34 selection kit system (Milteny Biotec, Bergisch, Gladbach, Germany), from small aliquots of leukapheresis products collected from either healthy donor or a patient undergoing stem/progenitor cell collection after granulocytecolony stimulating factor treatment for non-hematologic malignancy at Klinikum Krollwitz Hospital Halle, Germany, following their informed consent. After magnetic selection, more than 85% of the cells expressed the CD34 antigen. An aliquot containing 5 Â 10 5 CD34 þ cells was cultured in Iscove's modified Dulbecco's medium with 20% heat-inactivated fetal calf serum, 100 ng/ml Flt3-ligand, 100 ng/ml of stem cell factor, 100 ng/ml thrombopoietin, 100 ng/ml of interleukin-6 (IL-6) and 50 ng/ml of IL-3, 100 U/ml penicillin/streptomycin and 2 mM L-glutamine. The cells were transfected with various expression constructs using AMAXA nucleofection technology essentially as described by the manufacturer and analyzed for CD11b and CD15 expression by flow cytometry.
Cell lines, antibodies and treatments
Human myeloid cell lines U937 and K562-ER-C/EBPa were cultured under standard conditions. b-Estradiol and retinoic acid (RA) (Sigma-Aldrich, Munich, Germany) were used at a concentration of 1-5 mM and 10 À6 M, respectively. The antibodies used in this study were purchased from Santa Cruz (Heidelberg, Germany); for C/EBPa, SC-61 (14AA), SC-9315 (N-19) Max, SC-765 (C-124) and c-Myc, SC-42 (C-33) and Molecular Probes, Gmbh, Karlsruhe, Germany).
Immunoprecipitation and immunoblotting
The immunoprecipitation (IP) was performed from 500-1000 mg nuclear extracts of U937 cells in an IP buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% NP-40, 0.25% sodium deoxycholate), followed by washing in the buffer (50 mM Tris pH 7.5, 0.1% NP-40, 0.05% sodium deoxycholate) with respective antibodies (Santa Cruz) and the corresponding IgGs as controls. A Western blot analysis was used to confirm the identity of immunoprecipitated and/or co-precipitated proteins as described previously. 23 Alternatively, the immunocomplexes were incubated with urea lysis buffer for further proteomic analysis.
Proteomic analysis: two-dimensional gel electrophoresis and protein identification by mass spectrometry
The proteomics methodology was used essentially as described recently by our group. 34 Transient transfections using AMAXA and effectene Effectene transfection reagent (Qiagen, Gmbh, Hilden, Germany) and lipofectamine (Invitrogen, Gmbh, Karlsruhe, Germany) were used for transient transfections according to the manufacturer's instructions. Transient transfections were carried out with minimal promoter/luciferase construct, which has been derived from an oligo 5 0 -GATCCAGATTGCGCAATCG-3 0 by self-annealing, followed by ligation into a BamHI site of the thymidine kinase (TK) promoter and co-transfected with expression plasmids for hC/EBPa, Renilla Luciferase-null and/or Max as described. 23 The Nucleofector kit (AMAXA, Gmbh, Cologne, Germany) was used essentially as described by the manufacturer. A 5 mg portion of plasmid DNA constructs was used for each transfection and the transfection efficiency was analyzed using a plasmid with eGFP marker (2 mg). For CD34 þ and U937 cells, nucleofector solution kits used were VPA-1003 and VCA-1003 with nucleofection programs U-08 and V-01, respectively. The voltages are automatically adjusted according to the program and are essentially 110 V AC with a frequency of 50-60 Hz and a power consumption of 16 VA/fuse.
Immunofluorescence and flow cytometry U937 cells (3 Â 10 5 ), under uninduced condition or induced with RA (Sigma-Aldrich), were cytocentrifuged on glass slides with coverslips, fixed using 1:1 methanol/acetone and permeabilized using 0.3% Triton X. After blocking in PBG (0.5% BSA, 0.045% Fish-gelatin in phosphate-buffered saline) containing 5% FBS, the fixed cells were incubated with anti-C/EBPa (antigoat; Santa Cruz), anti-Max (anti-rabbit; Santa Cruz) and antiMyc (anti-mouse; Santa Cruz) antibodies, followed by incubation with corresponding Alexa Fluor 488 chicken anti-goat, Alexa Fluor 594 chicken anti-rabbit and anti-mouse IgG secondary antibodies (Molecular Probes) and 4 0 ,6 0 -diamidino-2-phenylindole dihydrochloride (DAPI, 1 mg/ml) for 15 min. The cells were mounted in aqueous mounting medium and the images were acquired and analyzed using a fluorescence microscope ( Â 100, Â 60). Flow cytometry was performed for CD11b, CD14 and CD15 expression on Bectin Dikinson flow cytometer, using the supplied analysis software.
Quantitative real-time PCR
RNA isolation from CD34 þ and U937 cells, transfected with different expression constructs, by TRIZOL (Invitrogen, Germany) was followed by cDNA synthesis using standard conditions. Equal amount of cDNA was taken for a subsequent quantitative real-time PCR (Q-RT-PCR) using the Quantitech SyBR Green PCR kit (Qiagen, Germany) in a Rotor-Gene RG-3000 (Corbett Research, Sydney, Australia). The delta ct value (Dct) was then calculated from the given ct value by the formula Dct ¼ ct sample Àct control ). The fold change was calculated as fold change ¼ 2 
Chromatin immunoprecipitation assay
Logarithmically growing and differentiating U937 cells (B1 Â 10 8 cells) were fixed with formaldehyde (final concentration 1% (v/v)) in serum free RPMI-1640 medium, at 41C for 1 h. Glycine was added to a final concentration of 0.125 M to stop cross-linking. Fixed cells were pelleted by centrifugation and sequentially washed and sonicated (five times for 20 s each) to make soluble chromatin. Samples of total chromatin were taken at this point to use as a positive control in the PCRs (input chromatin). Antibodies against C/EBPa, Max and c-Myc were used overnight at 41C. After serial elution, washing and cross-link reverse, the samples were extracted twice with phenol/ chloroform and precipitated with ethanol overnight in the presence of 20 mg glycogen as a carrier. DNA fragments were recovered by centrifugation, resuspended in ddH 2 O, and used for PCR amplification. For detection of immunoprecipitated C/EBPa promoter region, two primers, forward (5 0 -ACCGC TACCGACCACGTGGGCG-3 0 ) and reverse (5 0 -AGCACCTC CGGGTCGCGAATGG-3 0 ), specific for a 280 bp region in the cellular C/EBPa promoter that encompasses the C/EBP site were used for Q-RT-PCR amplification.
Results
Identification of Max, a heterodimeric partner of Myc, as a novel interacting protein of C/EBPa
To identify interacting proteins of C/EBPa in vivo under physiological conditions on a global level, we applied proteomics technique coupled with mass spectrometry using the IP conditions of endogenous C/EBPa from myeloid U937 cells as a model system.
Under our experimental conditions, we could specifically immunoprecipitate endogenous C/EBPa from the nuclear extracts of U937 cells ( Figure 1a ) and co-immunoprecipitate other endogenous proteins (as positive controls) such as c-Jun and CDK4 (Figure 1b and data not shown) that were not present in the isotype IgG control. Immunocomplexes were further processed for proteomic analysis. The protein spots excised from the 2D gels ( Figure 1c , spots are numbered) were identified by MALDI-TOF MS. Additionally, the individual bands were excised from Coomassie/silver-stained sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels ( Figure 1d ) and processed for LC-MS/MS. From both screens, we were able to reveal the identity of 10 proteins by MS, which specifically interact with C/EBPa ( Table 1) . Among these proteins, we identified Max as one interacting partner of C/EBPa. C/EBPa was also identified by MS analysis of the corresponding band (Figure 1d ), thereby serving as a control for our experimental setup. Proteins in other bands could not be determined because of the poor quality of the spectrum. The discovery of Max as a novel C/EBPa partner is intriguing because of the role Max plays in switching of the complexes during myeloid differentiation. 24 We therefore (c) Silver-stained 2D gels showing proteins specifically interacting with C/EBPa. C/EBPa was immunoprecipitated from nuclear extracts using anti-C/EBPa antibody (anti-rabbit; Santa Cruz) and the immunocomplex separated in the first dimension by pH 4-7 IPGphor strips followed by their separation in the second dimension using 12% SDS-PAGE. As a specificity control, we used immunoprecipitation with IgG under similar conditions. (d) Silver-stained SDS-PAGE gels after IP with anti-C/EBPa and anti-IgG. The bands were excised and peptide mixture after trypsin digestion was run on a reverse-phase high-pressure liquid chromatography and the peptides identified by MALDI-TOF-TOF (Applied Biosystems, Darmstadt, Germany).
selected Max for further functional and biological characterization.
C/EBPa and Max interact in a cellular setting: confirmation of proteomics data
To confirm the observed interaction of Max with CEBPa by an alternative technique, we performed reciprocal immunoprecipitation. Our results demonstrate that C/EBPa interacts with Max and vice versa ( Figure 2a ) in vivo, and thereby confirm proteomic results. It is important to note that for the same amounts of nuclear extracts used (5 and 10 mg) as input controls, the levels of the two transcription factors are dramatically different, which is likely due to Max being more stable than C/EBPa.
BR3 region of C/EBPa is involved in its interaction with Max
To investigate the protein domains that might be involved in C/EBPa-Max interaction, we performed co-immunoprecipitation studies using different mutants of C/EBPa as shown. C/EBPa and its various mutants (kind gift from Dr Alan Friedman; Figure 2b ) were transiently transfected into 293 cells, and cotransfected with an expression plasmid for Max (a kind gift from Dr Dirk Eick) containing a carboxy-terminal HA tag. 25 Max was then immunoprecipitated from nuclear extracts using anti-Max antibody. The associated complexes were assayed by immunoblotting for C/EBPa using anti-C/EBPa antibody. Our results demonstrate that C/EBPa could be co-immunoprecipitated when IP was performed using anti-Max antibody in samples in which wild-type C/EBPa: wild-type Max, GZ/LZ C/EBPa: wild-type Max and L1-2V C/EBPa: wild-type Max were coexpressed (Figure 2c, lanes 4, 3, 1, respectively) . However, C/EBPa could not be co-immunoprecipitated in immunoprecipitated samples in which basic region mutant BR3-C/EBPa: wild-type Max was co-expressed ( Figure 2c, lane 2) . We also show that Max could be specifically immunoprecipitated (as controls) with immunoblot for Max using anti-HA antibody (Figure 2c, lower panel) . The relative expression of C/EBPa mutants was the same (data not shown). These data show that the basic region of C/EBPa is involved in its interaction with Max in a cellular setting. Furthermore, we observed that wild-type Max and its basic region mutants have the same ability to interact with C/EBPa (Supplementary Figure S1a and b) .
C/EBPa and Max colocalize
Given the fact that C/EBPa and Max are nuclear transcription factors and the observation that they interact in vivo, we next investigated the localization of these proteins by indirect immunofluorescence in myeloid U937 cells. We observed both endogenous C/EBPa and Max to be localized in intranuclear structures (Figure 3a ) and the overlay of the two images shows 
C/EBPa-Max but not Myc-Max remains colocalized during granulocytic differentiation of myeloid U937 cells
We next investigated the effect on C/EBPa-Max colocalization when the cells were triggered for granulocytic differentiation by RA for 24 h. We observed intranuclear staining with C/EBPa and Max antibodies, and the overlay of the two images shows that both proteins remain colocalized even after RA treatment of the cells ( Figure 3b, panel 4 ; yellow signal). As Max is associated with Myc, we also analyzed their localization in U937 cells. We observed that endogenous Myc-Max colocalize in the nucleus under uninduced condition (Figure 3a , panels 5 and 6). On the other hand, no intranuclear c-Myc signal could be detected after RA treatment ( Figure 3c, panel 4 ; only green signal from Max). We next investigated the expression of c-Myc, Max and C/EBPa before and after RA treatment from various fractions (whole-cell lysates, nuclear fraction (NF) and cytoplasmic fraction (CF)) by Western blotting, using specific antibodies (Figure 3d) . Our results revealed that the c-Myc protein level was drastically decreased in all the three fractions (Figure 3d , upper and lower panels) by RA. However, C/EBPa was undetectable in the CF and slightly increased in the NF by RA when analyzed by immunoblotting. Dot blot analysis revealed the presence of CEBPa in the CF as well. This indicates that the concentration of C/EBPa in the CF is quite low, so as not to be detected by immunoblotting (data not shown). Max, on the other hand, was relatively unchanged under induced and uninduced conditions. These data demonstrate that retention/ colocalization of C/EBPa-Max, and not Myc-Max heterocomplexes, in the nucleus might be important events during granulocytic differentiation of U937 cells.
Max enhances the ability of C/EBPa to transactivate a minimal thymidine kinase promoter hanced the ability of C/EBPa to transactivate a minimal TK promoter containing two CCAAT binding site in a dosedependent manner (Figure 4a ). In control experiments, no effect of Max on C/EBPa activity was observed when promoter with no CCAAT binding sites was used, whereas C/EBPa alone was able to transactivate the minimal promoter construct ninefold. Similar results were obtained with myeloid U937 cells (Figure 4b ). Interestingly, co-transfection studies with the human B2200 bp C/EBPa promoter (which has intact E-box site and no CCAAT site) revealed that C/EBPa alone was unable to transactivate the promoter, whereas, co-transfection of Max led to a significant increase in the promoter activity (Figure 4c ). It is important to point out that Max itself does show some activation.
C/EBPa and Max associate in vivo: a Myc-Max-Mad link
To further elucidate the mechanism by which Max augments the transcriptional activity of C/EBPa, we hypothesized that Max might associate with the hC/EBPa promoter in vivo because similar to C/EBPa, Max also possesses a DNA binding basic region. To test this possibility, we performed quantitative radioactive and non-radioactive chromatin immunoprecipitation (ChIP) in U937 cells ( Figure 5 ). Chromatin was subjected to IP by using antibodies directed against C/EBPa, c-Myc and Max. The presence of C/EBPa promoter was detected by amplifying a promoter region using primers specific for a 280 bp region in the C/EBPa promoter that encompasses the CACGTG site (commonly referred to as E-box; Figure 5a) . The E-box is conserved in the human and mouse C/EBPa promoter (Figure 5a ). We observed that under normal physiological conditions (uninduced), endogenous c-Myc and Max appeared on C/EBPa promoter and there was undetectable endogenous C/EBPa occupancy on the hC/EBPa promoter (Figure 5b ). IP using an isotype-matched IgG served as a negative control. We next investigated the affect on heterocomplex formation at the hC/EBPa promoter upon differentiation by RA. We observed that both Max and C/EBPa appeared on C/EBPa Figure S2d) by using short hairpin RNA (shRNA) against Max (cat. no. RHS1764-9690535; Open Biosystems, Heidelberg, Germany) and control shRNA (cat. no. RHS1707; Open Biosystems). Cells were transfected with expression plasmids for C/EBPa alone and/or co-expressed with shRNA against Max, control shRNA, and the cells cultured in media containing puromycine. After selection, the cells were analyzed for granulocytic differentiation, using CD15 expression as a marker. Our results revealed that C/EBPa alone induces granulocytic differentiation (CD15 þ ) five-to six-fold as compared with the mock-transfected CD34 þ (Figure 6d ). Coexpression of Max shRNA led to a significant decrease in CD15 þ population (about twofold), whereas control shRNA did not lead to any significant reduction in CD15 þ population (Figure 6d , compare histograms). The reduction of Max protein level with shRNA was confirmed by Western blotting and Max shRNA did not affect the expression of C/EBPa (Figure 6e ). In conclusion, we propose a model shown as Figure 6f . Thus, Max is important for C/EBPa-mediated effects on granulocytic differentiation and might have an important role in stem cell development. 
Discussion
It has become increasingly clear that interaction of C/EBPa with other nuclear proteins plays an important role not only in lineage commitment and differentiation in the hematopoietic system but also in the pathogenesis of AML. Although the lineage commitment decision by C/EBPa was proposed by our laboratory to involve the functional inactivation of the myeloid master regulator PU.1 and/or its co-activator c-Jun through protein-protein interactions, 6,7 relatively little is known about how C/EBPa interacts with other nuclear proteins to activate gene transcription. The results presented in this article provide evidence that Max, a heterodimerization partner of Myc, is a novel, functionally and biologically important co-activator of
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CD11b CD15 CEBPa. C/EBPa and Max not only colocalize but also the heterocomplex is preferentially formed on the hC/EBPa promoter during granulocytic differentiation, thereby contributing to increased transactivation and differentiation capacity of C/EBPa. We used MS-based proteomic analysis as a means of identifying the interacting partners of C/EBPa, utilizing IP of C/EBPa from myeloid U937 cells as a model system. U937 cells are a good model system for studying myeloid differentiation in general, as they are bipotential and can be differentiated into granulocytic lineage by RA and in particular, with respect to the functions of C/EBPa, as a threefold level of C/EBPa protein (above the level of endogenous C/EBPa) in U937 cells is sufficient for their granulocytic differentiation. 26 In addition to nine other proteins (see Table) , we identified Max, an essential heterodimerization partner of Myc, 16 as a novel interacting partner of C/EBPa in our screen (Figure 1 ). The discovery of Max as a novel C/EBPa partner is intriguing because of the role Max plays in switching of the complexes during myeloid differentiation. 24 Of particular importance is the fact that transgenic mice carrying an inserted transgene encoding Max have been shown to exhibit a 50-to 60-fold elevation of blood neutrophils. 27 Additionally, Max is an essential heterodimerization partner of Myc family members to regulate transcription 11 and c-Myc is an important target of C/EBPa. 26 We confirmed the in vivo interaction of C/EBPa with Max by IP technique and showed that the basic DNA-binding region of C/EBPa is involved in this interaction, as the mutant of CEBPa (C/EBPa BR3), which lacks DNA-binding region, could not be co-precipitated with Max ( Figure 2 ). C/EBPa BR3 carries mutations in four amino acids, residues Arg297, Lys298, Arg300 and Lys302. 28 Of these, only Arg300 is expected to contact DNA. Neither the BR3 nor the Leu12Val variants bind DNA, suggesting that interaction with Max is likely via Arg297, Lys298 and/or Lys302. Arg297 is known to participate in the interaction between C/EBPa and E2F. 8 Further study is required to pin point the exact amino acid involved in the C/EBPa and Max interaction.
GCSFR
The endogenous C/EBPa and Max proteins are not distributed evenly throughout the nucleoplasm (Figure 3 ), but are localized in intranuclear structures within the nucleus. These structures represent, presumably, centromeres, which are chromosomal structures associated with intranuclear chromosome positioning and cell cycle regulation. Interestingly, C/EBPa is associated with cell cycle regulation. 29, 30 In other cell systems, such as pituitary progenitor GHFT1-5 cells, C/EBPa has been shown to concentrate at chromatin surrounding the centromeres. 31 The observation that C/EBPa-Max but not Myc-Max remain colocalized during granulocytic differentiation (Figure 3 ) indicates that these intranuclear structures (centromeres) are selectively targeted by C/EBPa-Max during granulocytic differentiation. We observed the occupancy of the hC/EBPa promoter by Max in vivo under physiological conditions, and recruitment of more C/EBPa whereas Max is retained on the promoter during granulocytic differentiation. It is possible that the C/EBPaÀMax heterocomplex regulates the balance of acetylated histones to modify chromatin structure at the hC/EBPa promoter and lead to transcriptional activation, as was shown by our results. In fact, TIP60, a histone acetyl transferase, was identified as an interacting partner of C/EBP to regulate histone acetylation at the hC/EBPa promoter a in an alternative approach (Bararia et al., manuscript submitted for publication). To our knowledge, this is a first report showing occupancy of the hC/EBPa promoter by Max in vivo.
The occupancy by Max of the hC/EBPa promoter raises a possibility that Myc could also form a part of the complex under physiological conditions, as Max requires dimerization with Myc for efficient DNA binding. In fact, it was shown that purified Myc þ Max heterodimers form stable complexes on the mouse C/EBPa promoter that includes the USF binding site. 21 The USF DNA recognition site CACGTG (which is the same as the E-box, occupied by Myc-Max) is found in both the human and the mouse C/EBPa promoter, and the USF binding site (for HLH-bZIP) is crucial for activation of the hC/ EBPa promoter by C/EBPa. 32 Our colocalization and ChIP data (Figures 4 and 5 ) and the data that C/EBPa is co-precipitated with Myc IP (unpublished observation) support this Myc-Max link. Thus, it is tempting to speculate that C/EBPa exists in association with the Myc-Max-Mad network to regulate differentiation under cellular settings. Given that the C/EBPa-Max heterocomplex is formed on hC/EBPa promoter, specifically during granulocytic differentiation, this would mean that the balance between such complexes, under the influence of growth and differentiation signals, could be an important part of a molecular switch that is regulating genes important for growth and differentiation.
By using overexpression studies, we have demonstrated that enforced expression of C/EBPa and Max in human hematopoietic CD34 þ cells induces granulocytic differentiation. The role of C/EBPa in the transition from CMPs to GMPs in myeloid progenitors has been recently characterized. 3 The role of Max in inducing granulocytic differentiation indicates that Max can activate myeloid differentiation program either independent of C/EBPa or in association with it. In vivo interaction and retention of C/EBPa-Max heterocomplex in myeloid cells ( Figures 2, 4 and 5) and inhibition of differentiation-inducing capacity of C/EBPa by stable silencing of Max using shRNA against MAX in CD34 þ cells ( Figure 6 ) suggest CEBPa-Max association likely plays an important role in this process of myeloid progenitor differentiation. A very recent data from Alan Friedman's group has shown the role of C/EBPa in monopoiesis. 33 This means that the commitment decisions do not necessarily depend upon a single transcription factor but, in fact, on a number of cooperating factors.
In summary, we conclude that Max is a biologically and functionally important and relevant interacting partner of C/EBPa and has important co-activator functions for C/EBPainduced granulocytic differentiation in myeloid progenitors.
